Across TCGA pan-cancer cohorts, NUDT11 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NUDT11 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NUDT11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NUDT11 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, GBM, and UCEC are the cancer types where NUDT11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.342	0.984	.006	6	view →
GBM	DFS	Tertile	All	0.517	0.303	.031	5	view →
UCEC	OS	Tertile	All	0.563	1.000	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: NUDT11 tumor-vs-normal RNA expression · all NUDT11 data types